180 related articles for article (PubMed ID: 9310250)
1. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage.
Ring P; Johansson K; Höyhtyä M; Rubin K; Lindmark G
Br J Cancer; 1997; 76(6):805-11. PubMed ID: 9310250
[TBL] [Abstract][Full Text] [Related]
2. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer.
Gallegos NC; Smales C; Savage FJ; Hembry RM; Boulos PB
Surg Oncol; 1995; 4(2):111-9. PubMed ID: 7551259
[TBL] [Abstract][Full Text] [Related]
3. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors.
Terada T; Okada Y; Nakanuma Y
Hepatology; 1996 Jun; 23(6):1341-4. PubMed ID: 8675149
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases and their inhibitors in gastric cancer.
Murray GI; Duncan ME; Arbuckle E; Melvin WT; Fothergill JE
Gut; 1998 Dec; 43(6):791-7. PubMed ID: 9824606
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors.
Murashige M; Miyahara M; Shiraishi N; Saito T; Kohno K; Kobayashi M
Jpn J Clin Oncol; 1996 Oct; 26(5):303-9. PubMed ID: 8895669
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti-metastatic ruthenium complex.
Sava G; Capozzi I; Bergamo A; Gagliardi R; Cocchietto M; Masiero L; Onisto M; Alessio E; Mestroni G; Garbisa S
Int J Cancer; 1996 Sep; 68(1):60-6. PubMed ID: 8895542
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
Schwandner O; Schlamp A; Broll R; Bruch HP
Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
[TBL] [Abstract][Full Text] [Related]
8. Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma.
Joo YE; Seo KS; Kim J; Kim HS; Rew JS; Park CS; Kim SJ
J Korean Med Sci; 1999 Aug; 14(4):417-23. PubMed ID: 10485622
[TBL] [Abstract][Full Text] [Related]
9. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases.
Zeng ZS; Guillem JG
Br J Cancer; 1995 Sep; 72(3):575-82. PubMed ID: 7669564
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
11. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer.
Grignon DJ; Sakr W; Toth M; Ravery V; Angulo J; Shamsa F; Pontes JE; Crissman JC; Fridman R
Cancer Res; 1996 Apr; 56(7):1654-9. PubMed ID: 8603416
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome.
Ara T; Fukuzawa M; Kusafuka T; Komoto Y; Oue T; Inoue M; Okada A
J Pediatr Surg; 1998 Aug; 33(8):1272-8. PubMed ID: 9722003
[TBL] [Abstract][Full Text] [Related]
13. MMP and TIMP expression pattern in pleural effusions of different origins.
Eickelberg O; Sommerfeld CO; Wyser C; Tamm M; Reichenberger F; Bardin PG; Solèr M; Roth M; Perruchoud AP
Am J Respir Crit Care Med; 1997 Dec; 156(6):1987-92. PubMed ID: 9412584
[TBL] [Abstract][Full Text] [Related]
14. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.
Jones JL; Glynn P; Walker RA
J Pathol; 1999 Oct; 189(2):161-8. PubMed ID: 10547569
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma.
Kikuchi R; Noguchi T; Takeno S; Kubo N; Uchida Y
Br J Cancer; 2000 Jul; 83(2):215-8. PubMed ID: 10901373
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
[TBL] [Abstract][Full Text] [Related]
17. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinases and their inhibitors.
Kugler A
Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
[TBL] [Abstract][Full Text] [Related]
19. Positive correlation between inhibitors of matrix metalloproteinase 1 and matrix metalloproteinases in malignant ovarian tumor tissues.
Kikkawa F; Tamakoshi K; Nawa A; Shibata K; Yamagata S; Yamagata T; Suganuma N
Cancer Lett; 1997 Nov; 120(1):109-15. PubMed ID: 9570393
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
